Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026.
Rhea-AI Summary
Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and corporate developments.
Registered participants receive dial-in details; a replay will be available about one hour after the call through March 12, 2026 with conference ID 3024961.
Positive
- None.
Negative
- None.
Details
News Market Reaction – AEMD
In the Feb 4 session, AEMD declined 3.86%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Quarter end date
- December 31, 2025
- Fiscal third quarter reporting period
- Earnings release time
- 4:15 p.m. ET
- Fiscal Q3 2025 results on February 12, 2026
- Conference call time
- 4:30 p.m. ET
- Fiscal Q3 2025 conference call on February 12, 2026
- US toll-free dial-in
- 1-844-836-8741
- Participant dial-in for live conference call
- International dial-in
- 1-412-317-5442
- International participant dial-in for live call
- Replay end date
- March 12, 2026
- Replay available until this date
- Replay US/Canada dial-in
- 1-855-669-9658
- Access number for recording of the call
- Replay conference ID
- 3024961
- ID required to access conference replay
Previous Conferences,earnings date Reports
-
Announced Q2 results release timing and post-close conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034a255186. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through March 12, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-on-february-12-2026-302678752.html
SOURCE Aethlon Medical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.